Fig. 4 | Nature Communications

Fig. 4

From: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

Fig. 4

The association of PFS and OS with ctDNA level measured by the average VAF of clonal mutations. Left, Patients were divided into two groups by ctDNA level. High ctDNA level group (higher than median of 0.18, dot line) was significantly associated with shorter PFS. Three patients were excluded from PFS analysis for three different reasons, including one patient who did not receive any treatment based on the patient's choice, one patient received surgery, and one could not offer out-patient otherapeutic records. Right, Patients were divided into two groups using the median ctDNA level of 0.18. Significantly shorter OS was observed in patients with higher ctDNA level (dot line). Small-cell lung cancer (SCLC) may evolve under treatment. But tumor tissues are often not available to study evolution of SCLC. Here, the authors utilize circulating tumor DNA to investigate the genomic evolution and subclonal architecture of SCLC during therapy

Back to article page